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Abstract Adiponectin and resistin, two recently identi¢ed adi-
pocyte-speci¢c secretory factors, are able to modulate insulin
actions in target tissues. To investigate their expression and
hormonal regulation in brown adipocytes, we used the brown
adipocyte cell line T37i, which, beside uncoupling protein ex-
pression, secretes leptin. Adiponectin and resistin mRNA were
detected as a function of cell di¡erentiation. Both transcripts
were expressed at relatively high levels in di¡erentiated T37i
cells, reaching maximal levels on day 7, while resistin expression
drastically fell afterwards. These stable transcripts (t1=2s 8 h)
were di¡erentially regulated by factors involved in insulin re-
sponsiveness. Insulin and thiazolidinedione, a peroxisome prolif-
erator-activated receptor Q agonist, stimulated resistin expres-
sion two- to four-fold in di¡erentiated T37i cells, whereas
adiponectin mRNA levels increased 1.5^2-fold. In contrast,
dexamethasone and isoproterenol reduced by two-fold the level
of adiponectin and resistin transcripts in di¡erentiated T37i
cells. This study provides the ¢rst direct evidence that di¡er-
entiated brown adipocytes are endocrine cells capable of ex-
pressing adiponectin and resistin. The complex hormonal regu-
lation of their expression in brown adipocytes clearly di¡ers
from that reported in white adipose tissue, pointing to di¡er-
ential physiological and pathophysiological implications of
brown fat in energy homeostasis.
, 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
For a long time white adipose tissue (WAT) was commonly
viewed exclusively as an inert storage depot for triglycerides
but this consideration is no longer true. Adipocytes have
proved to be highly active cells with potent autocrine, para-
crine and endocrine functions because they are able to secrete
a wide range of protein factors including leptin [1], tumor
necrosis factor [2], interleukin-6 [3], plasminogen activator in-
hibitor-1 [4], angiotensinogen, and acylation-stimulating pro-
tein [5].
Since the discovery of leptin, there has been great interest in
these adipose tissue-derived secretory factors because they are
believed to play an important role, particularly in situations of
overloaded adipose tissue, in which they participate in the
development of metabolic complications observed in obesity,
diabetes, or insulin resistance.
Recently, two novel factors have been identi¢ed in white
adipocytes. The ¢rst one, called adipocyte complement-related
protein of 30 kDa, adipoQ or adiponectin, was discovered
¢rst [6,7] and was described as an important insulin-sensitizing
hormone which is down-regulated in insulin resistance and
obesity and replenishment of which in adiponectin-de¢cient
states improves insulin sensitivity. A recent search for genes
that are down-regulated by thiazolidinedione (TZD) antidia-
betic drugs in mouse adipocytes led to the discovery of a
second factor called resistin [8]. This latter circulates in the
mouse, with increased levels in obesity, and has e¡ects on
glucose homeostasis that oppose those of insulin, suggesting
that resistin is a potential link between obesity and insulin
resistance.
Further studies investigated adiponectin and resistin gene
expression only in white adipose cells and indicated that ex-
pression of these genes is under complex hormonal regulation,
raising sometimes contradictory conclusions, especially con-
cerning the biological role of resistin.
Beside the energy-storing WAT, mammals possess a speci-
alized type of fat, the brown adipose tissue (BAT). This adi-
pose tissue has absolutely separate physiological functions.
Indeed, BAT is characterized by its thermogenic functions
because it has the ability to dissipate energy and to provide
heat. This results from the activity of the uncoupling proteins
(UCP) which translocate protons through the inner membrane
of mitochondria, uncouple oxidative phosphorylation and by-
pass the last enzymatic step of the respiratory chain, ATP
synthase [9]. Therefore, BAT plays a major role in the regu-
lation of body temperature, especially in small animals such as
mice or rats. In human infants, BAT may provide a similar
role, however the importance of BAT in adults remains to be
elucidated.
Brown adipocytes have also won the status of endocrine
cells because it has been shown that they are also able to
express and secrete leptin in their environment [10]. However,
no information is available concerning the expression and the
hormonal regulation of adiponectin and resistin transcripts in
the BAT. We have recently established the T37i cell line,
derived from a hibernoma developed in a transgenic mouse
in which the expression of SV40 large T antigen was placed
under the control of the proximal promoter of the human
mineralocorticoid receptor gene [11]. T37i cells are capable
of di¡erentiating into mature brown adipocytes upon insulin
and triiodothyronine exposure. During this di¡erentiation
process, adipogenic gene activation occurs including those of
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adipocyte-speci¢c fatty acid binding protein 2 (aP2), lipopro-
tein lipase (LPL), and peroxisome proliferator-activated re-
ceptor Q2 (PPARQ2) [12]. More importantly, expression of
UCP1, characteristic of brown adipocytes, but also UCP2
and UCP3 has been also demonstrated in this cell line [13].
Therefore, the T37i cell line represents a suitable model to
study BAT physiology.
The aim of the present study was to examine whether adi-
ponectin and resistin are expressed in brown adipocytes. We
next investigated the hormonal regulation of both hormones
in this cell line. Surprisingly, we report that insulin is the
major stimulator of resistin expression and slightly increases
the level of adiponectin transcripts. Moreover, we demon-
strate that TZD is also a potent stimulator of adiponectin
and resistin gene expression. In contrast, glucocorticoids and
L-adrenergic ligands drastically decrease the levels of adipo-
nectin and resistin transcripts. Taken together, our results in-
dicate that both adipocyte-speci¢c secretory factors are under
complex hormonal regulations in the BAT, which are clearly
distinct from those described in the WAT, especially regarding
the e¡ects of insulin and TZD.
2. Materials and methods
2.1. Cell culture
T37i cells were cultured in DMEM/Ham’s F12 medium (Invitrogen,
Pontoise, France) supplemented with 10% fetal calf serum, 2 mM
glutamine, 100 IU/ml penicillin, 100 Wg/ml streptomycin, 20 mM
HEPES and grown at 37‡C in a humidi¢ed atmosphere with 5%
CO2. Di¡erentiation into mature brown adipocytes was achieved
under standard conditions by incubating subcon£uent undi¡erentiated
T37i cells with 2 nM triiodothyronine (Sigma Chemical Co., St. Louis,
MO, USA) and 20 nM insulin (Invitrogen) for 7 days [11]. Adiponec-
tin and resistin expression were thereafter analyzed by ribonuclease
protection assays (RPA). Cells were generally incubated for 8 h in
serum-free medium before treatment with various hormones for 18 h.
All experiments were performed with T37i cells between passages 10
and 20.
2.2. Subcloning of the mouse adiponectin and resistin gene by RT-PCR
Total RNA was extracted from di¡erentiated T37i cells and from
mouse BAT using the TRIZOL reagent (Invitrogen). Brie£y, 2 Wg of
total RNA were reverse-transcribed with 200 units of reverse tran-
scriptase using the Superscript1 II kit (Invitrogen) according to the
manufacturer’s recommendations. Resistin and adiponectin cDNA
were then ampli¢ed for 30 cycles in a total volume of 25 Wl containing
1UPCR bu¡er (50 mM KCl, 20 mM Tris^HCl, pH 8.4), 200 WM
dNTPs, 1.5 mM MgCl2, 10 pmol of sense and antisense primers,
and 0.25 units of platinum Taq Polymerase (Invitrogen). Adiponectin
cDNA (532 bp) was ampli¢ed using the following sense (5P-GA-
CGTTACTACAACTGAAGAGC-3P) and antisense (5P-CATTC-
TTTTCCTGATACTGGTC-3P) oligonucleotide primers and resistin
cDNA (386 bp) was ampli¢ed using the following sense (5P-ACT-
GAGTTGTGTCCTGCTAAG-3P) and antisense (5P-CCACGCT-
CACTTCCCCGACATC-3P) oligonucleotide primers. The thermal cy-
cling program was 95‡C for 45 s, following a hybridization step at
56‡C (adiponectin and resistin) for 45 s, and an elongation step at
72‡C for 45 s. Each cDNA was run on a 2% agarose gel and puri¢ed
from the gel using the Qiaquick PCR Puri¢cation Kit Protocol (Qia-
gen, Courtaboeuf, France). Adiponectin and resistin cDNA were
thereafter subcloned into the pGEM-T easy cloning plasmid (Prom-
ega, Madison, WI, USA). The sequencing analysis of these cDNA
con¢rmed that the PCR products subcloned corresponded to adipo-
nectin (GenBank1 accession number MMU37222) and resistin (Gen-
Bank1 accession number AF323080), respectively.
2.3. Analysis of transcripts by RPA
In vitro synthesis of riboprobes was achieved using the adiponectin-
PGEM-T easy and resistin-PGEM-T easy plasmids linearized by BglII
and ClaI, respectively. Adiponectin and resistin K-32P-labeled anti-
sense riboprobes were then synthesized with T7 RNA polymerase
(Promega). The mouse L-actin riboprobe, used as an internal control,
was synthesized with T7 RNA polymerase after digestion of the L-ac-
tin-pGEM3 plasmid by Bsu36I.
RPAs were performed as previously described [10]. Twenty micro-
grams of total RNA, isolated from T37i cells using Trizol (Invitro-
gen), were hybridized overnight at 50‡C in a formamide/PIPES hy-
bridization bu¡er with 4U105 cpm adiponectin riboprobe, 4U105
cpm resistin riboprobe and 2U105 cpm L-actin riboprobe. Non-hy-
bridized RNA was digested at 30‡C for 1 h with a ribonuclease A and
T1 mixture followed by a 30 min proteinase K and sodium dodecyl
sulfate treatment, at 37‡C. After phenol^chloroform extraction and
ethanol precipitation, protected fragments were electrophoresed on a
6% polyacrylamide/urea gel. Gels were thereafter dried and ¢xed in
10% acetic acid. Radioactivity was counted generally overnight with
an InstantImager (Packard, Meriden, CT, USA) followed by auto-
radiography. Results are expressed in arbitrary units and corre-
sponded to the ratio between adiponectin- or resistin-speci¢c counts
versus L-actin signal.
Unprotected adiponectin riboprobe migrated at 240 bases with a
protected fragment migrating at 179 bases. Unprotected resistin ribo-
probe migrated at 335 bases with a protected fragment migrating at
280 bases. Unprotected L-actin riboprobe migrated at 158 bases with
a protected fragment migrating at 137 bases.
2.4. Drugs
Dexamethasone and isoproterenol were purchased from Sigma
whereas insulin was purchased from Invitrogen. TZD (rosiglitazone
or BRL 49653) was a generous gift from Dr. R. Negrel (Sophia
Antipolis, Nice, France).
2.5. Statistical analysis
Student’s t-tests were performed to analyze the data by use of the
computer software InStat version 2.01 for Macintosh (GraphPad
Software, San Diego, CA, USA). Values were considered signi¢cantly
di¡erent at P6 0.05.
3. Results and discussion
3.1. Adiponectin and resistin genes are expressed in
di¡erentiated T37i cells
Expression of adiponectin and resistin mRNA was ¢rst ex-
amined by RT-PCR in the T37i cell line as a function of the
di¡erentiation state. As shown in Fig. 1A, a 532 bp product,
100% identical to the adiponectin gene transcript, as con-
¢rmed by cDNA sequencing, was detected in di¡erentiated
T37i cells as well as in mouse BAT. Moreover, these cells
also expressed resistin mRNA since a 386 bp amplicon,
100% identical to the resistin gene transcript, was also ob-
served (Fig. 1B). However, neither adiponectin nor resistin
transcripts were detected in undi¡erentiated T37i cells suggest-
ing that adiponectin and resistin gene activation occurs during
the adipocyte di¡erentiation process. These results are com-
parable to those obtained in the WAT since expression of
both transcripts was reported only in fully di¡erentiated mu-
rine and human white adipose cells [6,8,14,15].
Quanti¢cation of adiponectin and resistin mRNA levels by
RPA revealed that expression of both hormones increased
progressively during brown adipocyte di¡erentiation progres-
sion and reached a maximal level on day 7 (Fig. 1C^F). This
coincided with the cell morphological changes characteristic
of brown adipocytes as well as the sequential activation of
adipogenic gene expression (LPL, PPARQ2 and aP2), as al-
ready reported [12]. Interestingly, we noted that adiponectin
mRNA levels remained relatively high even on day 11 of the
di¡erentiation process (Fig. 1E) whereas resistin mRNA levels
dramatically decreased after day 7 (Fig. 1F), possibly due to
an autocrine mechanism that down-regulates the level of re-
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sistin mRNA. This latter result contrasts with that observed in
3T3-L1 cells, in which resistin expression peaked on day 4 and
remained high even on day 12 [16], pointing to a tissue spec-
i¢city of the BAT versus WAT regarding resistin expression.
Of note, both adiponectin and resistin transcripts represented
abundant messengers in the T37i cells, the level of adiponectin
mRNA being always 10-fold higher than that of resistin, con-
sistent with its status of most abundant gene transcript in
adipose tissue [17]. These ¢ndings therefore suggest that adi-
ponectin and resistin play important roles in brown adipocyte
physiology.
Adiponectin and resistin gene expression could also be con-
sidered as markers of di¡erentiation, together with UCP1, in
the T37i cell line, since these genes were expressed exclusively
in fully di¡erentiated cells. This expression of adiponectin and
resistin transcripts in di¡erentiated T37i cells strengthens the
idea that brown adipocytes are endocrine cells since they are
possibly able to secrete these hormonal factors as well as
leptin, as previously reported [10]. Thus, our cell line appears
to be an appropriate system to investigate the hormonal reg-
ulation of these novel adipocyte-speci¢c secretory factors in
brown adipocytes.
3.2. Hormonal regulation of adiponectin gene expression in
di¡erentiated T37i cell
With the aim of understanding how adiponectin and resistin
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Fig. 1. Adiponectin and resistin genes are expressed in T37i cells. A,B: RT-PCR analyses of adiponectin (A) and resistin (B) gene expression.
M: marker ladder, xX174 RF DNA/HaeIII (Invitrogen); lane 1: undi¡erentiated T37i cells ; lane 2: di¡erentiated T37i cells on day 4 of the
di¡erentiation process; lane 3: di¡erentiated T37i cells on day 8 of the di¡erentiation process; lane 4: mouse interscapular BAT. Negative con-
trol was performed for each experimental condition by omitting the reverse transcriptase (3 symbol). Arrows indicate the expected size of the
PCR products. C,D: Time-dependent expression of adiponectin mRNA (C) and resistin mRNA (D) in T37i cells during di¡erentiation. This il-
lustrates one representative experiment. On di¡erent days of culture (from day 1 to day 11), total RNA was extracted and processed for RPA
using speci¢c probes for adiponectin or resistin together with L-actin. Signals were thereafter quanti¢ed by InstantImager and expressed as fold
induction of adiponectin (E) or resistin (F) expression.
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transcripts were regulated in the BAT, we treated di¡erenti-
ated T37i cells on day 7 of the di¡erentiation process with
di¡erent mediators known to a¡ect insulin sensitivity, includ-
ing insulin, dexamethasone, TZD and isoproterenol. Adipo-
nectin and resistin expression was thereafter analyzed by
RPA.
Preliminary results showed that the level of adiponectin and
resistin mRNA remained high in di¡erentiated T37i cells even
after incubation with 0.4 WM actinomycin D (data not
shown), indicating that these two transcripts are relatively
stable with a half-life t1=2 of s 8 h. We thus decided to in-
cubate di¡erentiated T37i cells for 8 h in serum-free medium
before an overnight treatment with 20 nM insulin, 100 nM
dexamethasone, 100 nM TZD or with 1 WM isoproterenol.
Fig. 2 indicates that insulin slightly increased by 1.4-fold
the level of adiponectin transcripts (P6 0.01 vs. control). A
similar increase in adiponectin transcripts was also obtained
with 100 nM insulin (data not shown), indicating that the
stimulation was already maximal at 20 nM insulin. This is
consistent with the high sensitivity of T37i cells to insulin
action with an ED50 of 0.1 nM insulin as measured by the
stimulation of leptin release [10] or glucose transport in these
cells (unpublished results). The stimulatory e¡ect of insulin on
adiponectin expression observed in T37i cells contrasts with
that reported in the 3T3-L1 cells in which insulin rapidly
induced a strong decrease in adiponectin transcripts [18].
The opposite e¡ect of insulin on adiponectin gene expression
provides additional support for important functional di¡er-
ences between the BAT versus the WAT.
Compared to insulin, TZD was a more potent stimulator of
adiponectin expression, increasing adiponectin transcripts by
two-fold (P6 0.001 vs. control). This result was comparable
to those obtained in the 3T3-L1 cell model in which this
antidiabetic drug enhances both mRNA expression and secre-
tion of adiponectin [19,20]. It was also shown that PPARQ
agonists were able to increase adiponectin plasma levels in
obese and diabetic mouse models [19] as well as in humans
[20], supporting the notion that adiponectin is a marker of
PPARQ activation in vivo and plays a major role in the reg-
ulation of glucose metabolism and body weight.
In contrast to insulin and TZD, dexamethasone decreased
the level of adiponectin mRNA by approximately 50%
(P6 0.001 vs. control). This result was in agreement with
those obtained in 3T3-L1 cells [18] or in human adipose vis-
ceral tissue [21], where glucocorticoids were shown to be po-
tent inhibitors of adiponectin expression. We also observed a
two-fold decrease in the level of adiponectin transcripts in
T37i cells treated with isoproterenol, a result consistent with
the 75% inhibition of adiponectin expression reported in mu-
rine white adipocytes [22]. This e¡ect was mediated via the
activation of the L3-adrenergic receptor and protein kinase A
(PKA)-dependent pathway, supporting a role of decreased
adiponectin in catecholamine-induced insulin resistance [22].
Altogether, we have demonstrated that the adiponectin
gene is highly expressed in di¡erentiated brown adipocytes
and provided new insights into the regulation of this key
hormone. Because adiponectin is able to a¡ect insulin sensi-
tivity most notably in the liver [23] and the muscle [24], any
alteration of its expression may contribute to the development
of insulin resistance [25]. Indeed, adiponectin plasma levels
were shown to be decreased in obese [7,26] and diabetic pa-
tients [27,28], as well as in lipodystrophic patients [29], con-
sistent with the involvement of adiponectin in insulin resis-
tance and metabolic complications. Moreover, adiponectin
was thought to be a physiological factor modulating endothe-
lial functions thereby constituting a link to obesity and vas-
cular diseases [30,31]. The exact contribution of the BAT-de-
rived adiponectin in the development of such pathologies is
likely to be less prominent than that of the WAT-secreted
adiponectin. However, adiponectin locally secreted from the
BAT may exert important metabolic e¡ects through paracrine
and/or autocrine mechanisms as recently proposed in bone
marrow where this hormone had a major impact on lympho-
hematopoiesis and adipocyte di¡erentiation [32].
3.3. Hormonal regulation of resistin gene expression in
di¡erentiated T37i cell
Fig. 3 presents the hormonal regulation of resistin tran-
scripts by the same mediators. Our results indicated that re-
sistin expression was strongly induced by insulin in a mag-
nitude order of three- to four-fold (P6 0.001 vs. control),
suggesting that resistin gene transcription in T37i cells is
tightly and rapidly regulated by insulin. This ¢nding is remi-
niscent of the transcriptional control of ob gene expression by
insulin observed in brown adipocytes [10], which involved
activation of both phosphatidylinositol 3-kinase- and mito-
gen-activated protein kinase-dependent pathways. Unlike the
stimulatory e¡ect of insulin on resistin expression in the BAT,
whether insulin is a positive or negative modulator of resistin
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Fig. 2. Hormonal regulation of adiponectin gene expression in dif-
ferentiated T37i cells. Di¡erentiated T37i cells were incubated on
day 7 of the di¡erentiation state for 8 h in serum-free medium be-
fore treatment for 18 h with insulin 20 nM (INS), dexamethasone
100 nM (DXM), TZD 100 nM, or isoproterenol 1 WM (ISO). Total
RNA was extracted and processed for RPA using speci¢c probes
for adiponectin and L-actin. Signals were quanti¢ed by Instant-
Imager and expressed as relative expression of adiponectin. Results
represent meansRS.E.M. for 9^18 independent determinations.
**P6 0.01, ***P6 0.001 vs. control.
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expression in the WAT is still a matter of controversy. Indeed,
some authors reported that in vivo adipocyte resistin gene
expression and protein were clearly increased during fasting/
refeeding or by insulin administration [8,33] while others dem-
onstrated a strong decrease in resistin expression in 3T3-L1
cells after incubation with insulin [16,34].
With respect to TZD, we showed that this antidiabetic drug
was able to increase the level of resistin mRNA by two- to
three-fold (P6 0.001 vs. control). This result was very surpris-
ing because resistin was initially identi¢ed as a gene down-
regulated by TZD [8]. The inhibitory e¡ect of TZD on resistin
expression in 3T3-L1 cells was con¢rmed by subsequent stud-
ies [16,34,35]. However, the e¡ects of TZD on resistin expres-
sion in WAT are also controversial since an increase in adi-
pose tissue resistin mRNA levels was observed in ob/ob mice
and Zucker rats treated with PPARQ agonists [36]. The im-
portant functional di¡erences observed between the brown
T37i and the white 3T3-L1 adipocyte cell model in terms of
their di¡erential responsiveness to TZD may actually rely on
distinct mechanisms of gene transcriptional activation, most
notably the function of PPARQ and C/EBPK, the two major
adipogenic regulators. Indeed, at variance with the WAT, C/
EBPK and PPARQ do not seem to be required for BAT di¡er-
entiation and function [37,38].
As illustrated in Fig. 3, we next demonstrated that incuba-
tion of T37i cells by dexamethasone or isoproterenol de-
creased by 50% the level of resistin mRNA (P6 0.001 vs.
control). The inhibitory e¡ect of glucocorticoids on resistin
expression resembles that previously reported for leptin ex-
pression in the T37i brown adipocyte model [10] but more
work is needed to clearly de¢ne the molecular mechanisms
restricting the expression of these adipocyte-speci¢c genes.
Along this line, catecholamines, through activation of the
PKA cascade, were also potent negative regulators of resistin
gene expression in 3T3-L1 cells [16,40].
Finally, to summarize our results, a schematic representa-
tion of the regulatory e¡ects of various stimuli on resistin and
adiponectin expression in brown adipocytes compared to that
observed in white adipocytes is presented in Fig. 4. We pro-
vide the ¢rst direct evidence that di¡erentiated brown adipo-
cytes expressed both resistin and adiponectin genes which are
under strikingly di¡erent hormonal regulation than that pre-
viously reported in the WAT. These ¢ndings bring additional
support for major functional di¡erences between these two
types of adipose tissue and suggest their distinct involvement
in various pathophysiological disorders. Indeed, given the ma-
jor role played by resistin and adiponectin as factors regulat-
ing insulin sensitivity, BAT could be seen as a novel endocrine
source of hormones, not only in rodents but also in humans
[9,41,42]. The major impact of BAT in energy homeostasis
has been highlighted by recent reports on animal models. A
marked susceptibility to diet-induced obesity, diabetes and
insulin resistance was observed in mice with ablation of
BAT [43] and BAT-speci¢c insulin receptor knockout mice
unexpectedly presented with a defect in insulin secretion and
impaired glucose tolerance [44] suggesting a functional link
between brown fat and L cell function. In addition, it is
more likely that brown adipocytes might locally secrete resis-
tin and adiponectin resulting in important paracrine and au-
tocrine actions within speci¢c locations including white fat
[39], bone marrow [32] or mammary glands [45]. Further stud-
ies are needed to precisely determine the complex regulatory
cross-talk between adipocyte-speci¢c secretory factors. It also
remains to elucidate how the endocrine, paracrine or auto-
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Fig. 3. Hormonal regulation of resistin gene expression in di¡erenti-
ated T37i cells. Di¡erentiated T37i cells were incubated on day 7 of
the di¡erentiation state for 8 h in serum-free medium before treat-
ment for 18 h with insulin 20 nM (INS), dexamethasone 100 nM
(DXM), TZD 100 nM, or isoproterenol 1 WM (ISO). Total RNA
was extracted and processed for RPA using speci¢c probes for resis-
tin and L-actin. Signals were quanti¢ed by InstantImager and ex-
pressed as relative expression of resistin. Results represent means
RS.E.M. for 9^20 independent determinations. ***P6 0.001 vs.
control.
Brown adipocyte
Resistin
Thiazolidinedione
Insulin Glucocorticoids
β-adrenergic
 ligands
Adiponectin
Resistin
Thiazolidinedione
Insulin Glucocorticoids
β-adrenergic
 ligands
Adiponectin
White adipocyte
Fig. 4. Schematic models of hormonal regulation of adiponectin
and resistin gene expression in brown and white adipocytes.
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crine interplay among adipocytokine signaling pathways co-
ordinately regulates insulin’s actions and glucose and lipid
metabolism to ¢nally control adipose tissue mass and body
weight.
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